SCHEMBL9004344

SCHEMBL9004344

CCCCCC(=O)O[C@@H]1[C@@H](OC(=O)CCCCC)[C@H](OP(=O)(O)O)[C@@H](O)[C@@H](OP(=O)(O)O)[C@H]1OC(=O)CCCCC

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.53
TLR4 O00206 1/20 0.50
LY96 Q9Y6Y9 1/20 0.50
ITPR3 Q14573 7/20 0.47
ITPR2 Q14571 3/20 0.47
ITPR1 Q14643 3/20 0.47
AKT1 P31749 2/20 0.47
INPP5A Q14642 1/20 0.47
INPPL1 O15357 1/20 0.47
NR5A2 O00482 1/20 0.45
NR5A1 Q13285 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
NAAA Q02083 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9000966 0.98 SMPD1 (0.55) SMPD1TLR4LY96ITPR3ITPR2
SCHEMBL4285698 0.92 ITPR3 (0.52) SMPD1TLR4LY96ITPR3ITPR2
SCHEMBL3075893 0.92 LY96 (0.53) SMPD1TLR4LY96NAAA
SCHEMBL3063341 0.92 LY96 (0.53) SMPD1TLR4LY96NAAA
SCHEMBL3075469 0.90 LY96 (0.55) SMPD1TLR4LY96GPR55NAAA
SCHEMBL3082731 0.90 LY96 (0.55) SMPD1TLR4LY96GPR55NAAA
SCHEMBL9000958 0.89 ITPR3 (0.52) SMPD1ITPR3ITPR2ITPR1AKT1
SCHEMBL3653390 0.88 ITPR3 (0.53) SMPD1TLR4LY96ITPR3ITPR2
SCHEMBL3075504 0.87 LY96 (0.48) SMPD1TLR4LY96ITPR3ITPR2
SCHEMBL3076907 0.87 LY96 (0.48) SMPD1TLR4LY96ITPR3ITPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0730460-A1 THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS PERSTORP AB (SE) 1996-09-11 EP disclosed
WO-1995014477-A1 THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS PERSTORP AB (SE) 1995-06-01 WO disclosed